A Phase II Clinical Trial of Sequential Neoadjuvant Chemotherapy with Ifosfamide, Doxorubicin, and Gemcitabine, followed by Cisplatin, Gemcitabine, and Ifosfamide in Locally Advanced Urothelial Cancer: Final Results

Ítems similars

• Phase II Clinical Trial of Neoadjuvant Alternating Doublet Chemotherapy With Ifosfamide/Doxorubicin and Etoposide/Cisplatin in Small-Cell Urothelial Cancer
  per: Siefker-Radtke, Arlene O., et al.
  Publicat: (2009)
• A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer
  per: McConkey, David J., et al.
  Publicat: (2015)
• Neoadjuvant Chemotherapy in Small Cell Urothelial Cancer Improves Pathologic Downstaging and Long-term Outcomes: Results from a Retrospective Study at the MD Anderson Cancer Center
  per: Lynch, Siobhan P., et al.
  Publicat: (2012)
• Final Results of Sequential Doxorubicin Plus Gemcitabine and Ifosfamide, Paclitaxel, and Cisplatin Chemotherapy in Patients With Metastatic or Locally Advanced Transitional Cell Carcinoma of the Urothelium
  per: Milowsky, Matthew I., et al.
  Publicat: (2009)
• Front-line Treatment with Gemcitabine, Paclitaxel and Doxorubicin for Patients with Unresectable or Metastatic Urothelial Cancer and Poor Renal Function: Final Results from a Phase II Study
  per: Siefker-Radtke, Arlene O., et al.
  Publicat: (2015)